en
Mol2Med™ provides an API-sparing, 3–6-week pathway to early, data-driven solid-form and formulation decisions. Using ~500 mg–1 g of material, integrated models and targeted experiments deliver a decision-ready physicochemical profile, an objective read on oral bioavailability potential, and recommendations (salt/cocrystal vs free form; conventional vs amorphous solid dispersion). Resolving these choices at lead or candidate stage reduces reformulation cycles, conserves material, and de-risks progression to oral dosage development.
Subscribe to be the first to get the updates!
